214 related articles for article (PubMed ID: 36640111)
21. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.
Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J
Cancer Manag Res; 2020; 12():3247-3255. PubMed ID: 32440221
[TBL] [Abstract][Full Text] [Related]
22. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
[TBL] [Abstract][Full Text] [Related]
23. Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy.
Xia W; Chen J; Hou W; Chen J; Xiong Y; Li H; Qi X; Xu H; Xie Z; Li M; Zhang X; Li J
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047817
[TBL] [Abstract][Full Text] [Related]
24. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
[TBL] [Abstract][Full Text] [Related]
25. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.
Fu Y; Urban DJ; Nani RR; Zhang YF; Li N; Fu H; Shah H; Gorka AP; Guha R; Chen L; Hall MD; Schnermann MJ; Ho M
Hepatology; 2019 Aug; 70(2):563-576. PubMed ID: 30353932
[TBL] [Abstract][Full Text] [Related]
26. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
27. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
28.
Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma.
Tseng HC; Xiong W; Badeti S; Yang Y; Ma M; Liu T; Ramos CA; Dotti G; Fritzky L; Jiang JG; Yi Q; Guarrera J; Zong WX; Liu C; Liu D
Nat Commun; 2020 Sep; 11(1):4810. PubMed ID: 32968061
[TBL] [Abstract][Full Text] [Related]
30. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
31. Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3.
Arulanandam A; Lin L; Chang HM; Cerutti M; Choblet S; Gao P; Rath A; Bensussan A; Kadouche J; Teper D; Mandelboim O; Li W
Cells; 2023 Mar; 12(7):. PubMed ID: 37048069
[TBL] [Abstract][Full Text] [Related]
32. Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.
Zheng X; Liu X; Lei Y; Wang G; Liu M
Front Oncol; 2022; 12():824208. PubMed ID: 35251989
[TBL] [Abstract][Full Text] [Related]
33. Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC.
Kolluri A; Li D; Li N; Duan Z; Roberts LR; Ho M
Hepatol Commun; 2023 Feb; 7(2):e0022. PubMed ID: 36691969
[TBL] [Abstract][Full Text] [Related]
34. Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC.
Li D; Qin J; Zhou T; Li Y; Cheng X; Chen Z; Chen J; Zheng WV
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36896779
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
36. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma.
Wang P; Qin W; Liu T; Jiang D; Cui L; Liu X; Fang Y; Tang X; Jin H; Qian Q
Immunobiology; 2020 Jan; 225(1):151850. PubMed ID: 31522780
[TBL] [Abstract][Full Text] [Related]
37. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.
Li K; Qian S; Huang M; Chen M; Peng L; Liu J; Xu W; Xu J
Am J Transl Res; 2021; 13(1):156-167. PubMed ID: 33527015
[TBL] [Abstract][Full Text] [Related]
38. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
39. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
40. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]